E6AP, an E3 ubiquitin ligase negatively regulates granulopoiesis by targeting transcription factor C/EBPα for ubiquitin-mediated proteasome degradation

P Pati1, S Lochab1, JK Kanaujiya1, I Kapoor1, S Sanyal1, G Behre2 and AK Trivedi*1

CCAAT/enhancer-binding protein alpha (C/EBPα) is an important transcription factor involved in granulocytic differentiation. Here, for the first time we demonstrate that E6-associated protein (E6AP), an E3 ubiquitin ligase targets C/EBPα for ubiquitin-mediated proteasome degradation and thereby negatively modulates its functions. Wild-type E6AP promotes ubiquitin dependent proteasome degradation of C/EBPα, while catalytically inactive E6-associated protein having cysteine replaced with alanine at amino-acid position 843 (E6AP-C843A) rather stabilizes it. Further, these two proteins physically associate both in non-myeloid (overexpressed human embryonic kidney epithelium) and myeloid cells. We show that E6AP-mediated degradation of C/EBPα protein expression curtails its transcriptional potential on its target genes. Noticeably, E6AP degrades both wild-type 42 kDa CCAAT-enhancer-binding protein alpha (p42C/EBPα) and mutant isoform 30 kDa CCAAT-enhancer-binding protein alpha (p30C/EBPα), this may explain perturbed p42C/EBPα/p30C/EBPα ratio often observed in acute myeloid leukemia (AML). We show that overexpression of catalytically inactive E6AP-C843A in C/EBPα inducible K562-p42C/EBPα-estrogen receptor (ER) cells inhibits β-estradiol (E2)-induced C/EBPα degradation leading to enhanced granulocytic differentiation. This enhanced granulocytic differentiation upon E2-induced activation of C/EBPα in C/EBPα stably transfected cells (β-estradiol inducible K562 cells stably expressing p42C/EBPα-ER (K562-C/EBPα-p42-ER)) was further substantiated by siE6AP-mediated knockdown of E6AP in both K562-C/EBPα-p42-ER and 32dc13 (32D clone 3, a cell line widely used model for in vitro study of hematopoietic cell proliferation, differentiation, and apoptosis) cells. Taken together, our data suggest that E6AP targeted C/EBPα protein degradation may provide a possible explanation for both loss of expression and/or functional inactivation of C/EBPα often experienced in myeloid leukemia.

Cell Death and Disease (2013) 4, e590; doi:10.1038/cddis.2013.120; published online 18 April 2013

Subject Category: Cancer

CCAAT-enhancer-binding protein alpha (C/EBPα) is a key transcription factor required for differentiation of multiple cell types including myeloid cells.1 In hematopoiesis, C/EBPα regulates myeloid differentiation and granulopoiesis.2 C/EBPα mediates its functions by binding to promoters of its target genes and interacting with agonist (co-activators) and antagonist (repressor) proteins in a cell-type-specific manner.3,4 C/EBPα function is also modulated by post-translational modifications such as phosphorylation, SUMOylation, and ubiquitination.5–8 The functional activity of wild-type C/EBPα (42 kDa wild-type CCAAT-enhancer-binding protein alpha (p42C/EBPα)) is frequently perturbed in myeloid leukemia resulting in differentiation blockade.2,4 Notably, loss of function or expression of C/EBPα provides a platform for acute myeloid leukemia (AML) development.9 C/EBPα is mutated in ~9% of AML cases; reported mutations in C/EBPα comprise point mutations in basic leucine-zipper domain or N-terminus frame-shift mutations leading to formation of a dominant negative C/EBPα isoform (30 kDa mutant CCAAT-enhancer-binding protein alpha (p30C/EBPα)) encoded by same CEBPA from different translation start site.6,9,10–12 p30C/EBPα inhibits myeloid differentiation by exerting dominant negative functions over p42C/EBPα.11 Further, recent studies suggest that p42C/EBPα function is antagonized by protein–protein interactions. AML1/ETO binds C/EBPα, suppresses its transcriptional activity and thereby interferes with C/EBPα promoter autoregulation13 leading to reduced C/EBPα expression; c-Jun promotes proliferation and prevents differentiation by inhibiting C/EBPα DNA binding via interacting with leucine-zipper domain.14 Additionally, AML specific Flt3 mutations downregulate C/EBPα expression and contribute to leukemogenesis.15 Recently, we and others have shown C/EBPα

1Drug Target Discovery and Development Division, CSIR-Central Drug Research Institute, Sector-10, Jankipuram Extension, Lucknow, UP 226021, India and 2Division of Hematology and Oncology, University Hospital of Leipzig, Johannissallee 32A, 04103 Leipzig, Germany

*Corresponding author: AK Trivedi, Drug Target Discovery and Development Division, CSIR-Central Drug Research Institute, Room No LSS008, Sector-10, Jankipuram Extension, Sitapur Road, Lucknow, UP 226021, India. Tel.: +91 9839 7307 65; Fax: +91 9222 277119; E-mail: arun3vedi@cdri.res.in

Keywords: C/EBPα; E6AP; myeloid leukemia; differentiation; ubiquitination

Abbreviations: C/EBPα, CCAAT/enhancer-binding protein alpha; p42C/EBPα, 42 kDa wild-type CCAAT-enhancer-binding protein alpha; p30C/EBPα, 30 kDa mutant CCAAT-enhancer-binding protein alpha; E6AP, E6-associated protein; E6AP-C843A, E6-associated protein having cysteine replaced with alanine at amino-acid position 843; GST, glutathione sepharose transferase; siRNA, small interfering RNAs; HEK293T, human embryonic kidney epithelium; WCEs, whole-cell extracts; E2, β-estradiol; HSPs, heat shock proteins; AML, acute myeloid leukemia; PBS, phosphate-buffered saline; K562-C/EBPα-p42-ER, β-estradiol inducible K562 cells stably expressing p42C/EBPα-ER; 32Dc13, 32D clone 3, a cell line widely used model for in vitro study of hematopoietic cell proliferation, differentiation, and apoptosis

Received 14.9.12; revised 07.3.13; accepted 11.3.13; Edited by G Ciliberto

Open Access

© 2013 Macmillan Publishers Limited. All rights reserved. 2041-4889/13

www.nature.com/cddis
regulation at protein level via ubiquitin-mediated proteasome degradation.\textsuperscript{7,16} Phosphorylated JNK stabilizes C/EBP\textsubscript{x}, while inactive JNK facilitates its ubiquitination.\textsuperscript{7} Keeshan \textit{et al.},\textsuperscript{17} showed that Trib2 associates with p42/EBP\textsubscript{x} and promotes its proteasome-mediated degradation leading to increased p30C/EBP\textsubscript{x}/p42/EBP\textsubscript{x} ratio, commonly seen in AML. However, only two E3 ubiquitin ligases for C/EBP\textsubscript{x} are known till date: E3 ligase TRIM21 interacts with TRIB2 to downregulate C/EBP\textsubscript{x} in lung tumors, while Fbxw7 targets it in preadipocytes.\textsuperscript{18,19} Here, for the first time we report that E6-associated protein (E6AP), a homologous to E6AP carboxy terminus domain containing E3 ubiquitin ligase also targets C/EBP\textsubscript{x} for ubiquitin-mediated proteasome degradation.

E6AP, a 100-kDa cellular protein is a member of functionally related E3-ubiquitin-protein ligases defined by the domain homologous to the carboxy terminus hept domain.\textsuperscript{20} E3 ligases ubiquitinate and degrade several regulatory proteins including p53, p27, promyelocytic leukemia retinoic acid receptor \textalpha{} and others, which serve as tumor suppressors and cell-cycle inhibitors.\textsuperscript{21–24} Recently, using mass spectrometry based proteomics approach we identified E6AP as a target of tamoxifen.\textsuperscript{25} Moreover, Tamoxifen is reported to enhance C/EBP\textsubscript{x} expression in cell-type-specific manner, we hypothesized E6AP might be an E3 ubiquitin ligase for potentially degrades both forms of C/EBP\textsubscript{x} (Figure 1d,e and f).

To further examine C/EBP\textsubscript{x} degradation in the presence of E6AP in the nucleus, we performed immuno-fluorescence assay in 293T cells, which showed gradual degradation of C/EBP\textsubscript{x} in a dose-dependent manner (Supplementary Figure S1). Together, these data suggest that E6AP degrades C/EBP\textsubscript{x} in the nucleus.

\textbf{E6AP and C/EBP\textsubscript{x} physically interact with each other.} As E6AP targets C/EBP\textsubscript{x} for degradation, we hypothesized that these two proteins may physically interact; For this, we performed \textit{in vitro} glutathione sepharose transferase (GST) pull down using bacterially purified GST-E6AP and 293T nuclear extracts transfected with C/EBP\textsubscript{x}. After pull down, bead bound GST-E6AP with its interacting proteins from the lysates were resolved on 10% SDS-PAGE. Immunoblot with C/EBP\textsubscript{x} antibody showed that E6AP interacts with GST-E6AP in vivo interaction interaction between C/EBP\textsubscript{x} and E6AP. For co-immunoprecipitation studies, we also treated C/EBP\textsubscript{x} and E6AP transfected cells with proteasome inhibitor. Interestingly, prominent interaction was observed between C/EBP\textsubscript{x} and E6AP in the presence of MG132, apparently due to inhibition of proteasome pathway (Figure 2b).
E6AP degrades C/EBP\(\alpha\) via ubiquitin proteasome pathway and negatively affects its transactivation capacity. We showed E6AP destabilizes C/EBP\(\alpha\) and moreover, these two proteins also physically interact with each other. We, therefore, asked whether it involves ubiquitin-mediated proteasome degradation. For this, 293T cells were transiently transfected either with C/EBP\(\alpha\) or together with E6AP expression plasmids as indicated in Figure 3a. Twenty-four hours post transfection cells were treated with MG132 in C/EBP\(\alpha\) and E6AP co-transfected

Figure 1  E6AP inhibits C/EBP\(\alpha\) steady state levels. (a) HEK 293T cells were transfected with C/EBP\(\alpha\) (0.5 μg) along with increasing amounts of E6AP (0.5–2.0 μg). This was followed by immunoblotting with C/EBP\(\alpha\), E6AP and β-actin antibodies. (b) 293T cells were transfected with C/EBP\(\alpha\) (0.5 μg) along with increasing concentrations of E6AP-C843A (0.5–2.0 μg) and were followed by immunoblotting with C/EBP\(\alpha\), E6AP and β-actin antibodies. (c) 293T cells were transfected with C/EBP\(\alpha\) (0.5 μg), E6AP (2.0 μg) and E6AP mutant C843A (2.0 μg) as indicated. Post 24 h nuclear extracts were prepared, resolved on 10% SDS-PAGE and probed with C/EBP\(\alpha\), E6AP and GAPDH antibodies. GAPDH was used a control for cytoplasmic protein extract. (d, e) K562 cells were transfected with C/EBP\(\alpha\) (0.5 μg), E6AP (1.0, 2.0 μg) and E6AP-C843A (1.0, 2.0 μg). In the indicated condition, cells were treated with 25 μM MG132 3 h prior to cell lystate preparation. The blot was probed with C/EBP\(\alpha\), E6AP and β-actin antibodies. (f) 32Dc3 cells were transfected with C/EBP\(\alpha\) (0.5 μg), E6AP (0.5, 1.0, 1.5 and 2.0 μg) and E6AP-C843A (1.0, 2.0 μg). The blot was probed with C/EBP\(\alpha\), E6AP and β-actin antibodies. (g) 293T cells were transfected with p42C/EBP\(\alpha\) (0.5 μg), p30C/EBP\(\alpha\) (0.5 μg) and E6AP (1.0–2.0 μg) as indicated. Cells were treated with 25 μM MG132 3 h prior to lystate preparation in one of the conditions. Lysates were resolved on 10% SDS-PAGE and probed with C/EBP\(\alpha\), E6AP and β-actin antibodies.
condition followed by lystate preparation. Immunoblot with C/EBPα and E6AP antibody nicely showed that C/EBPα degradation is dramatically restored upon MG132 treatment (Figure 3a). This strongly suggests that E6AP promotes proteasomal degradation of C/EBPα. However, to further support the notion that E6AP-mediated C/EBPα degradation involves ubiquitin proteasome pathway, we performed in vivo ubiquitination assay by transfecting 293T cells with C/EBPα HA, Ubiquitin-His, E6AP and E6AP-C843A. Twenty-four hours post transfection, cells were harvested; C/EBPα was co-immunoprecipitated and probed with His antibody. Strong C/EBPα ubiquitination ladder was observed in C/EBPα, E6AP and His-Ubiquitin co-transfected cells, while mild ubiquitination was seen in cells co-transfected with C/EBPα, His-Ubiquitin and E6AP-C843A, suggesting E6AP indeed promotes ubiquitination of C/EBPα. Interestingly, more intense ubiquitinated ladder pattern was observed in cells treated with MG132, which apparently stabilized the ubiquitinated C/EBPα by inhibiting proteasome machinery (Figure 3b). This data affirms that ligase activity of E6AP promotes C/EBPα ubiquitination leading to its degradation via proteasome pathway.

As E6AP targets C/EBPα for degradation, we further asked if it affects C/EBPα transactivation potential. For this, we performed luciferase reporter assay on a minimal pTK promoter containing two C/EBP-binding sites. Indicated amounts of reporter vector and expression plasmids for C/EBPα, E6AP and E6AP-C843A were transfected in 293T cells. Twenty-four hours post transfection luciferase activity was measured, which showed co-transfection of E6AP with C/EBPα significantly inhibited C/EBPα transactivation potential in a dose-dependent manner (Figure 3c). Further, MG132 treatment efficiently restored C/EBPα transactivation potential even in the presence of E6AP. Additionally, co-transfection of E6AP-C843A with C/EBPα did not inhibit C/EBPα transactivation capacity. This clearly indicates that catalytically active E6AP negatively modulates C/EBPα protein stability and its biological functions.

**E6AP knockdown enhances C/EBPα expression and promotes differentiation in U937 cells.** C/EBPα is a key regulator of granulocyte development.\(^{30,31}\) Moreover, differentiation arrest in myeloid leukemia subtypes is attributed to functional inactivation of C/EBPα.\(^ {32}\) As we show that E6AP targets C/EBPα for proteasomal degradation, we sought to assess the protein expression levels of C/EBPα in some of the representative myeloid leukemia cell lines (U937, HL60, K562 and Kasumi-1) having diminished expression levels of C/EBPα. WCEs of indicated cell lines probed with E6AP antibody clearly showed ample expression of E6AP in these cells with K562 showing greatest expression (Supplementary Figure S4). To establish functional correlation between E6AP and C/EBPα expression in myeloid leukemia cells, we sought to assess C/EBPα protein levels in myeloid leukemia cell U937 after inhibiting E6AP by small interfering RNAs (siRNA). Notably, there is ample expression of E6AP in U937 cells (Supplementary Figure S4) and as a matter of fact it has reduced C/EBPα expression. We transiently transfected U937 cells with control siRNA and siE6AP (Figure 4a) (siE6AP efficacy was validated in MCF7 and K562 cells; Supplementary Figure S5). After indicated time points WCEs were prepared, resolved on 10% SDS-PAGE and immunoblotted with E6AP, C/EBPα and β-actin antibodies. Expectedly, it showed persistent decrease in E6AP protein levels and...
(in siE6AP transfected lanes) with concomitant increase in C/EBPα expression (Figure 4a). In fact, FACS flow cytometer analysis of U937 cells transiently transfected with siE6AP for 72 h also showed enhanced expression of myeloid differentiation marker cd11b (Figure 4b), suggesting E6AP inhibition in myeloid leukemia cells may overcome differentiation blockade, a common phenomenon observed in several leukemia subtypes.

E6AP and C/EBPα-ER physically interact in K562 cells stably expressing C/EBPα-ER. As we showed C/EBPα and E6AP physically interact both in vitro (Figure 2a) and in vivo (Co-Immunoprecipitation (Co-IP), Figure 2b), we further validated their interaction in physiologically relevant myeloid leukemia cells. We transiently transfected K562 and 32Dc13 cells with C/EBPα and E6AP either alone or together as indicated. Twenty-four hours post transfection, lysates were prepared and C/EBPα was immunoprecipitated using C/EBPα antibody. Co-immunoprecipitates were resolved on 8% SDS-PAGE, probed with C/EBPα antibody after stripping the same blot, which again confirmed in vivo interaction in K562 and 32Dc13 cells (Figures 5a and b; Supplementary Figure S6 shows uncropped Figure 5a). To further endorse their physical association, we assessed in vivo interaction between endogenous C/EBPα and E6AP from U937 cells. C/EBPα was co-immunoprecipitated using C/EBPα antibody from U937 WCEs and resolved on 8% SDS-PAGE (Figure 5c). Immunoblotting with C/EBPα and E6AP antibodies clearly showed in vivo interaction between these two proteins (Figure 5d). As we used β-estradiol inducible K562 cells stably expressing p42C/EBPα-ER (K562-C/EBPα-p42-ER) (detailed in Supplementary fig.S3), as a model cell line to further address biological relevance of their physical interaction, we, therefore, also confirmed interaction between these two proteins in these stable cells. We performed co-immunoprecipitation using C/EBPα antibody from WCEs of K562-ER, K562-p42C/EBPα-ER, and β-estradiol (E2)-induced K562-C/EBPα-p42-ER (induced for short period to avoid fast degradation of C/EBPα-ER) as indicated (Figure 5d). Immunoblot with E6AP followed with C/EBPα antibody after stripping the same blot nicely showed physical interaction between C/EBPα and E6AP. As expected prominent interaction was observed in MG132-treated conditions, obviously due to stabilization of C/EBPα (Figures 5a and d). Taken together, these results suggest that E6AP physically interacts with C/EBPα in myeloid cells and may promote its ubiquitin-mediated degradation.

E6AP inhibition in β-estradiol (E2) inducible K562 cells stably expressing C/EBPα-ER enhances granulocytic differentiation. As E6AP expression was higher in K562 cells where there are non-detectable levels of C/EBPα,34 we generated β-estradiol inducible K562 cells stably expressing C/EBPα-ER (Supplementary Figure S3) to demonstrate E6AP actions over C/EBPα functions. These stable cells (K562-p42C/EBPα-ER) express p42C/EBPα fused with ER ligand binding domain while control cells express only ER domain (K562-ER). These K562-C/EBPα-p42-ER cells are useful model system to study the dynamics of C/EBPα dependent granulocytic differentiation because they respond to β-estradiol
treatment by nuclear translocation. Upon nuclear translocation, C/EBPα binds and activates its target genes such as GCSFR3 and CEBPE. In stably transfected cells, this fusion protein stays in the cytoplasm bound with heat shock proteins (HSPs). Stimulation with E2 activates it by binding to ER domain of this fusion protein and this ligand binding relieves the HSPs bound to C/EBPα-ER, which then migrates to the nucleus and activates its target genes.

Notably, E2 binding to this fusion protein also promotes its degradation, and therefore, upon nuclear translocation C/EBPα-ER protein is rapidly eliminated within 24 h (Figure 6a). To verify that E6AP is involved in this rapid degradation of ligand bound C/EBPα-ER, we overexpressed E6AP-C843A in these cells. Twenty-four hours post transfection cells were stimulated with E2 and harvested after indicated time points. As shown in Figure 6b the rate of C/EBPα degradation is substantially inhibited in the presence of E6AP-C843A and C/EBPα protein is stabilized for longer duration. In fact, siE6AP transfection in these cells also caused significant reduction in rate of C/EBPα degradation (Figure 6c). This clearly indicates that E6AP promotes C/EBPα degradation, which can be modestly restored either by overexpression of E6AP-C843A or inhibition of E6AP by siE6AP; however, as E6AP inhibition is unable to completely restore C/EBPα expression; it is very likely that other E3 ligases may also regulate C/EBPα protein stability.

As transfection of E6AP-C843A in K562-C/EBPα-p42-ER cells inhibited the rate of C/EBPα-ER degradation, we assumed that overexpression of E6AP-C843A would enhance granulocytic differentiation upon E2 induction. For this, K562-C/EBPα-p42-ER cells were transfected with E6AP-C843A and 24-h post transfection, cells were induced with E2 for further 72 h and then subjected to FACS analysis for cd11b and its respective IgG-PE-conjugated antibodies for FACS analysis.
E6AP, an E3 ubiquitin ligase targets C/EBPα for degradation
P Pal et al

Discussion

Most cancers are caused by activating mutations in proto-oncogenes and/or inactivating mutations in tumor suppressor genes rendering corresponding proteins functionally inactive. Additionally, perturbed stability of these regulatory proteins is a major cause for functional impairment. The target proteins are usually degraded tightly by proteasome machinery, which involves ubiquitin attachment to the target proteins through a series of enzymatic reactions where E3 ligases are key players. E6AP is one such E3 ubiquitin ligase implicated in the degradation of tumor suppressor protein
p53 in conjunction with HPV viral E6 protein in some cancers.\textsuperscript{23} p53 degradation affects apoptosis and cell-cycle as it is chiefly involved in the regulation of these pathways. Like p53, there are several other cellular proteins reported to be regulated by E6AP.\textsuperscript{41–46}

\textit{C/EBP\textsubscript{a}} is a key regulator of cellular processes, such as proliferation arrest, adipocyte differentiation, and granulopoiesis in particular.\textsuperscript{34,47–49} We and others have previously shown that C/EBP\textsubscript{a} can be degraded via ubiquitin proteasome pathway; however, except Fbwx7, the E3 ligases involved in

**Figure 6** E6AP inhibition in \(\beta\)-estradiol (E2) inducible K562 cells stably expressing C/EBP\textsubscript{a}-ER enhances granulocytic differentiation. (a) K562-p42 C/EBP\textsubscript{a}-ER stable cells were induced with 5 \(\mu\)M E2 for the indicated time points. Lysates were resolved on 10% SDS-PAGE and probed with C/EBP\textsubscript{a}, E6AP and \(\beta\)-actin antibodies. (b) K562-p42 C/EBP\textsubscript{a}-ER stable cell line was transfected with E6AP-C843A and, post 24 h of transfection, was induced with 5 \(\mu\)M E2 for the indicated time points. Lysates were resolved on 10% SDS-PAGE and probed with C/EBP\textsubscript{a}, E6AP and \(\beta\)-actin antibodies. (c) K562-p42-C/EBP\textsubscript{a}-ER cells were transiently transfected with siE6AP. Post 24 h of transfection cells were induced with \(\beta\)-estradiol (5 \(\mu\)M) for the indicated time points. Lysates were resolved on 10% SDS-PAGE and probed with C/EBP\textsubscript{a}, E6AP and \(\beta\)-actin antibodies. (d) K562 p42-C/EBP\textsubscript{a}-ER stable clones were transfected with E6AP-C843A and were induced with 5 \(\mu\)M estradiol. After 72 h of induction cells were washed and labelled with cd11b and cd114-PE-conjugated antibodies for the FACS analysis. Results are representative of minimum three independent experiments.
its degradation has largely remained elusive. Here, for the first time we report that E6AP can also target C/EBPα for proteasomal degradation. We explored the role of E6AP in the ubiquitination of C/EBPα, their physical interaction and consequent relevance in myeloid differentiation. Here, we provide several lines of evidence that indicate E6AP is an E3 ubiquitin ligase for C/EBPα. First, E6AP promotes proteasomal degradation of C/EBPα (Figures 1a,c,d and e and Figures 3a and b). Further, we show E6AP also degrades p30C/EBPα (Figure 1f). Second, a catalytically inactive E6AP-C843A

Figure 7  E6AP inhibition leads to granulocytic differentiation in 32Dc3 cells. 32Dc3 cells were transfected with siE6AP and E6AP-C843A and were induced with G-CSF for the indicated time points. After (a) 3 days, (b) 9 days and (c) 15 days of induction cells were washed, cytospun and stained with May-Grünwald and Giemsa staining (bold arrows = granulocytes/neutrophils; simple arrows = apoptotic cells)
inhibits C/EBPα degradation (Figure 1b c and d). Third, we show that C/EBPα and E6AP physically interact in myeloid cells (Figures 2 and 5). Fourth, degradation of C/EBPα is via ubiquitin proteasome pathway (Figures 3a and b). Thus, these data implicate a direct role of E6AP in the proteasomal degradation of C/EBPα.

As a consequence of C/EBPα protein degradation mediated by E6AP, C/EBPα transactivation potential is compromised (Figure 3c), which showed E6AP may inhibit functional activity of C/EBPα. E6AP-mediated negative effects on the functional activity of C/EBPα were further addressed in K562-C/EBPα-p42-ER stable cells stably expressing C/EBPα-ER fusion protein. As shown in Supplementary Figure S3, there is expression of p42C/EBPα-ER in the K562 stable clones, which induces granulocytic differentiation upon E2 induction.

C/EBPα is required for granulocytic differentiation, and restoration of its proper function can enable leukemic stem and progenitor cells in AML and chronic myeloid leukemia myeloid blast crisis to overcome differentiation blockade and mature into functional effector cells.[27,50] It acts as a master switch between uncommitted proliferating progenitors and differentiated cells.[51] Thus, the downregulation and functional inactivation of C/EBPα is involved in tumorigenesis. Growing evidences reveal that alterations of the key myeloid transcription factor C/EBPα is involved in the pathogenesis of AML.[52–54] Importantly, different mechanisms lead to decreased C/EBPα function in different AML subtypes.[3,4] Therefore, enhancing/stabilizing C/EBPα protein expression or function in myeloid leukemia cells can be beneficial from therapeutic perspective. As restoration of C/EBPα in K562 cells promotes granulocytic differentiation,[27] we assumed stabilization of C/EBPα in these stable cells would have similar effects.

For this, we overexpressed E6AP-C843A in K562-C/EBPα-p42-ER stable cells and 24 h post transfection induced them with β-estradiol. Similarly, we knocked down E6AP in these cells using siE6AP and 24 h post transfection induced them with β-estradiol. Post 72 h E2 induction, FACS analysis for cd11b and cd114 expression confirmed that E6AP-C843A overexpression and/or siE6AP-mediated knockdown of E6AP in K562-C/EBPα-p42-ER stable cells substantially increases the percentage of cells undergoing differentiation in the presence of E2 (Figure 6).

Besides, E6AP knockdown in U937 cells also led to enhanced C/EBPα protein levels and subsequent myeloid differentiation (Figure 4). Moreover, biological effects of E6AP inhibition validated in a yet another myeloid differentiation model 32Dcl3 cells, also resulted in increased granulocytic differentiation (Figure 7), which further consolidated our data that E6AP targets C/EBPα for degradation and E6AP knock down or its functional inhibition may stabilize C/EBPα, leading to enhanced differentiation.

Henceforth, we propose a hypothetical model (Figure 8), which suggests that E6AP targets C/EBPα for degradation via ubiquitin proteasome pathway. As loss of C/EBPα expression is associated with leukenogenesis, our results predict a correlation between elevated levels of E6AP and loss of C/EBPα expression, as well as function in leukemic cells. Furthermore, inhibition of E6AP either via siE6AP or dominant negative E6AP-C843A stabilizes C/EBPα leading to enhanced granulopoiesis. Thus, targeting E6AP can have therapeutic implications in myeloid leukemia and other cancers where C/EBPα is a crucial cellular factor.

Materials and Methods
Cell culture and expression plasmids. HEK293T and K562 cells obtained from ATCC were cultured in DMEM and phenol red free RPMI-1640, respectively, supplemented with 10% fetal bovine serum (FBS) and antibiotics. IL-3 dependent murine myeloid 32Dcl3 cells were obtained from ATCC. 32Dcl3 cells were maintained in RPMI-1640 medium supplemented with 10% FBS, 1% PenStrep (Gibco, Grand Island, NY, USA) and 10 ng/ml murine IL-3 (Prospec, East Brunswick, NJ, USA) at 37 °C and 5% CO2. Notably, hnRNPs inhibit CEBPA mRNA translation in K562 cells and hence no detectable levels of C/EBPα are seen in these cells. Interestingly, ectopic expression of C/EBPα in these cells drives them to granulopoietic differentiation.[55] In contrast, 32Dcl3 cells are murine myeloid precursor cells that differentiate to mature granulocytes in response to G-CSF. Interestingly, ectopically expressed C/EBPα promotes and accelerates G-CSF driven differentiation of 32Dcl3 cells.

Plasmids and siRNA. Expression plasmids for pCDNA3.1-C/EBPα–HA,[48] pCDNA3.1-E6AP,[51] pCAG-HA-E6AP, pCAG-HA-C/EBPα-C843A,[56] pGEX4T-GST-E6AP55 were kind gifts from G. J. Darlington, Nihar Jana, Ikuo Shoji and Zafar Nawaz respectively; while pCDNA3-p42C/EBPα, Ubiquitin-his, p(C/EBP)/2TK-luc and pCDNA3-p30C/EBPα are previously described.[57] The siE6AP and scrambled siRNA, as well as siRNA transfection reagent Dharmafect were purchased from...
Dharmacon RNA Technologies (Lafayette, CO, USA). E6AP-C843A is a catalytically inactive form of E6AP where active site cysteine residue is substituted with alanine (C843A). This cysteine residue present in the catalytic domain transfers ubiquitin directly to the substrate via ubiquitin-enzyme cascade leading to their degradation.

**Generation of stable cell line.** pBabe-Puro-C/EBPα p42-ER and pBabe-Puro empty vector constructs were used for generating stable clones as previously described. For this, K562 cells were transfected with pBabe-Puro-p42CGEBPα-ER and empty vector, selection of cells was performed in RPMI-1640 supplemented with 10% FBS, 1× antibiotic solution and 2.0 μg/ml puromycin. Cells resistant to puromycin (2.0 μg/ml) were further cultured in puromycin supplemented medium for next 2 weeks. In total, six clones were selected by the serial dilution of cells. These six clones were cultured for another 2 weeks in RPMI-1640 supplemented with puromycin (2.0 μg/ml) and subsequently confirmed for C/EBPα-ER expression by immunoblotting (Supplementary Figure S2).

**Western blotting.** Cells were harvested after indicated time points using RIPA buffer (1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 5 mM EDTA and 50 mM Tris pH8.0) and equal amount of proteins were separated on 10% SDS-PAGE as previously described. Subsequently, proteins were transferred and immunoblotted using primary antibodies against C/EBPα, His, GST, β-actin, GAPDH (Santacruz Biotechnology, SantaCruz, CA, USA) and E6AP (Sigma-Aldrich, St. Louis, MO, USA).

**Immunofluorescence microscopy.** HEK293T cells were plated in chamber slide one day before transfection. Next day cells were transfected with C/EBPα and E6AP plasmids. Twenty-four hours after transfection cells were washed with phosphate-buffered saline (PBS), fixed in 4% paraformaldehyde for 10 min, permeabilized with 0.5% Triton X-100 in PBS for 5 min, washed with PBS, and then blocked with 1% BSA in PBS for 1 h. The cells were then incubated with primary antibodies C/EBPα and E6AP (1 : 200) overnight at 4°C. Next day, cells were washed thrice with PBS, incubated with Alexa Flour 594 and 488 secondary antibodies (1 : 250 dilutions) for 1 h; Again washed thrice with PBS followed by 4′, 6-diamidino-2-phenylindole staining (Sigma-Aldrich). Cells were then mounted with vectashield (Vector Laboratories, Burlingame, CA, USA) and were visualized using a confocal microscope (Leica, Wetzlar, Germany).

**Luciferase reporter assay.** 1×10^5 HEK 293T cells/well were plated 1 day before transfection. Next day cells were transfected with pTur-C/EBPα-luc promoter, C/EBPα, E6AP and E6AP mutant (E6AP-C843A). Twenty-four hours after transfection, cell extracts were assayed for luciferase activity, using luciferase assay reagent (Promega, Madison, WI, USA). Data are presented as means of triplicate values obtained from representative experiments.

**Co-Immunoprecipitation assay.** For Co-IP cell lysates were prepared in Laemmli buffer. Samples were separated on 10% SDS-PAGE and were subsequently immunoblotted with C/EBPα and E6AP antibody.

**GST-Pull down.** For GST-Pull down assay GST-E6AP protein was overexpressed in E.coli and was subsequently purified using immobilized glutathione sepharose beads (Amersham Bioscience/GE Healthcare, Pittsburg, PA, USA) in NETN buffer (20 mM Tris pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% NP40). Cell lysate of C/EBPα overexpressed in HEK293T cells were prepared in RIPA buffer. For pull down experiments, GST purified proteins were incubated with WCEs in NETN buffer for 3 h at 4°C on a rotating shaker. After pull down, protein bound GST sepharose beads were washed three times with NETN buffer. SDS loading dye was added to the beads and was resolved on 10% SDS-polyacrylamide gel, immunoblotted with GST and C/EBPα antibody to confirm the interaction.

**In vivo ubiquitination assay.** HEK293T cells were transfected with C/EBPα, E6AP and ubiquitin constructs. Post 24 h of transfection, cells were harvested and RIPA lysates were prepared. Subsequently, co-immunoprecipitation was performed with 2 μg of C/EBPα antibody using protein G agarose beads (Millipore). After preclearing, protein lysates were incubated with antibody and beads for 3 h. The co-immunoprecipitated proteins were then separated by 10% SDS-PAGE and probed with His antibody.

**Giems staining.** K562-C/EBPα-p42-ER and 32Dcl3 cells were cytops on slides; air-dried and were stained with May-Grünwald and Giemsa solution. For this, cells were stained with May-Grünwald solution for 5 min followed by washing with 1× PBS for 2 min. Meanwhile, Giemsa solution was diluted 1 : 20 ratio in PBS and slides were further stained in this diluted solution for 15--20 min. Cells were then washed in running tap water to remove the excess stain, air-dried and subjected to microscopic examinations under light microscope and were photographed.

**Conflict of interest**

The authors declare no conflict of interest.

**Acknowledgements.** Funding from Center for Research on Anabolic Skeletal Targets in Health and Illness (ASTHI), CSRIR (BSC2001), Department of Biotechnology (GAP006) to AKT and ICMR Senior Research Fellowship to PP is acknowledged. Institutional communication number for this article is 8425.

1. Birkenmeier EH, Gwynn B, Howard S, Jerry J, Gordon J, Landshuc LH et al. Tissue-specific expression, developmental regulation, and genetic mapping of the gene encoding CCAAT/enhancer binding protein. Genes Dev 1989; 3: 1146–1156.
2. Nerlov C. C/EBPα mutations in acute myeloid leukaemias. Nat Rev Cancer 2004; 4: 394–400.
3. Kochsmeider S, Halmos B, Levantini E, Tenen DG. Dysregulation of the C/EBPβ-zipper differentiation pathway in human cancer. J Clin Oncol 2009; 27: 619–628.
4. Trivedi AK, Pal P, Behne G, Singh SM. Multiple ways of C/EBPβ inhibition in myeloid leukaemia. Eur J Cancer 2008; 44: 1516–1523.
5. Ross SE, Radomka HS, Wu B, Zhang P, Wynn JM, Bajnok L et al. Phosphorylation of C/EBPβ inhibits granulopoiesis. Mol Cell Biol 2004; 24: 675–686.
6. Geleta M, Bakhit MY, Peer Zada AA, Christopet M, Pukkkan JA, Trivedi AK et al. Target proteins of C/EBPβ/p30 in AML. C/EBPβ/p30 enhances sumoylation of C/EBPβ/p30 via up-regulation of Ubc9. Blood 2007; 110: 3301–3309.
7. Trivedi AK, Baradía D, Christopet M, Peer Zada AA, Singh SM, Kieser A et al. Proteomic identification of C/EBPβ-BD multiprotein complex: JNK1 activates stem cell regulator C/EBPβ by inhibiting its ubiquitination. Oncogene 2007; 26: 1789–1801.
8. Behne G, Singh SM, Liu H, Bortolin LT, Christopet M, Radomka HS et al. Ras signaling enhances the activity of C/EBPβ alpha to induce granulocytic differentiation by phosphorylation of serine 245. J Biol Chem 2002; 277: 26293–26299.
9. Rosenauer F, Tenen DG. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol 2007; 7: 105–117.
10. Gartorf AB, Hofmann WK, Kawano S, Takeuchi S, Krug U, Kwok SH et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002; 99: 1332–1340.
11. Hata N, Iura J, Noki D, Komeno Y, Yamanabe-Okouchi I, Togami K et al. Two types of C/EBPβ mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models. Blood 2011; 117: 221–233.
12. Westendorf JJ, Yamamoto CM, Lenny N, Downing JR, Selsted ME, Hiebert SW. The gene encoding the transcription factor CCAAT/enhancer binding protein alpha, in acute myeloid leukemia. Blood 2002; 99: 1332–1340.
18. Grandinetti KB, Stevens TA, Ha S, Salamone RJ, Walker JR, Zhang J et al. Overexpression of TRB2 in human lung cancers contributes to tumorigenesis through downregulation of CEBPalpha. In Human Oncogene 2011; 30: 3328–3335.

19. Bengoechea-Alonso MT, Ericsson J. The ubiquitin ligase Fbxw7 controls adipocyte differentiation by targeting CEBPalpha for degradation. Proc Natl Acad Sci USA 2010; 107: 11817–11822.

20. Hubregtse JM, Scheffner M, Beaudenon S, Howley PM. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci USA 1995; 92: 5249.

21. Mishra A, Godavarthi SK, Jana NR. UBE3A/E6-AP regulates cell proliferation by promoting proapoptotic degradation of p27. Neuron Cell Death Differ 2009; 36: 26–34.

22. Talis AL, Huibregtse JM, Howley PM. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem 1998; 273: 6439–6445.

23. Scheffner M, Hubregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495–505.

24. Louria-Hayon I, Alsheich-Bartok O, Levav-Cohen Y, Silberman I, Berger M, Grossman T et al. E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ 2009; 16: 156–165.

25. Lochab S, Pai P, Kanaujya JK, Tripathi SB, Kapoor I, Bhatt ML et al. Proteomic identification of E6AP as a molecular target of tamoxifen in MCF7 cells. Proteomics 2012; 12: 1383–1377.

26. Cheng J, Yu DV, Zhou JH, Shapiro DJ. Tamoxifen induction of CCAAT enhancer-binding protein alpha is required for tamoxifen-induced apoptosis. J Biol Chem 2007; 282: 35353–35354.

27. Tavor S, Park D, Gery S, Vuong PT, Gombart AF, Koefler HP. Restoration of CEBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation. J Biol Chem 2003; 278: 52651–52659.

28. Bliang X, Scott by Sawyers CL, Friedman AD. CEBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood 1999; 94: 560–571.

29. Keeshan K, Sankil G, Corradini F, Perrotti D, Calabretta B. Transcription activation function of CEBPalpha is required for induction of granulocytic differentiation. Blood 2003; 101: 1281–1289.

30. Friedman AD, Keefe JR, Kummalue T, Liu H, Wang QF, Cleaves R. Regulation of hematopoietic fate choice, myeloid differentiation, and leukemogenesis. J Leukoc Biol 1998; 63: 4042–4050.

31. Rosmarin AG, Yang Z, Resendes KK. Transcriptional regulation in myelopoiesis: CEBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation. J Biol Chem 2003; 278: 52651–52659.

32. Bliang X, Scott by Sawyers CL, Friedman AD. CEBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood 1999; 94: 560–571.

33. Keeshan K, Sankil G, Corradini F, Perrotti D, Calabretta B. Transcription activation function of CEBPalpha is required for induction of granulocytic differentiation. Blood 2003; 101: 1281–1289.

34. Friedman AD, Keefe JR, Kummalue T, Liu H, Wang QF, Cleaves R. Regulation of hematopoietic fate choice, myeloid differentiation, and leukemogenesis. J Leukoc Biol 1998; 63: 4042–4050.

35. Friedman AD, Keefe JR, Kummalue T, Liu H, Wang QF, Cleaves R. Regulation of hematopoietic fate choice, myeloid differentiation, and leukemogenesis. J Leukoc Biol 1998; 63: 4042–4050.

36. Friedman AD, Keefe JR, Kummalue T, Liu H, Wang QF, Cleaves R. Regulation of hematopoietic fate choice, myeloid differentiation, and leukemogenesis. J Leukoc Biol 1998; 63: 4042–4050.

37. Chakraborty A, Tweardy DJ. Granulocyte colony-stimulating factor activates a 72-kDa E3-ubiquitin ligase that targets CEBPA double mutant AML as a distinctive disease entity. Blood 2011; 117: 2469–2475.

38. Singh SM, Trivedi AK, Behre G. CEBPalpha regulated microRNA-34a targets EZF3 during granulopoiesis and is down-regulated in AML with CEBPalpha mutations. Blood 2010; 116: 5638–5649.

39. Nakaz L, Lonard DM, Smith CL, Lev-Lehman E, Tsi S, Tsai MJ et al. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 1999; 19: 1182–1189.

40. Singh SM, Trivedi AK, Behre G. CEBPalpha-Signed mutations reduce granulocytic differentiation in human leukemic K562 cells. Biochem Biophys Res Commun 2003; 309: 692–694.

41. Pal P, Kanaujya JK, Lochab S, Tripathi SB, Bhatt ML, Singh PK et al. Evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011; 117: 2469–2475.

42. Holliin IK, van den Heuvel-Eibrink MM, Arensen-Peters ST, Zimmermann M, Peeters JK, Vaal PJ et al. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica 2011; 96: 384–392.

43. Pulikkan JA, Peramangalam PS, Dengler V, Ho PA, Preudhomme C, Meshinchi S et al. CEBPalpha regulated microRNA-34a targets EZF3 during granulopoiesis and is down-regulated in AML with CEBPalpha mutations. Blood 2010; 116: 5638–5649.

44. Nakaz L, Lonard DM, Smith CL, Lev-Lehman E, Tsi S, Tsai MJ et al. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 1999; 19: 1182–1189.

45. Singh SM, Trivedi AK, Behre G. CEBPalpha-Signed mutations reduce granulocytic differentiation in human leukemic K562 cells. Biochem Biophys Res Commun 2003; 309: 692–694.

46. Pal P, Kanaujya JK, Lochab S, Tripathi SB, Bhatt ML, Singh PK et al. 2-D gel electrophoresis-based proteomic analysis reveals that ormeloxifen induces G0-G1 growth arrest independent of DNA binding. J Biol Chem 2007; 282: 29200–29209.

47. Ueki RM, Friedman AD, McKnight SL. CCAAT-enhancer binding protein: a component of a differentiation switch. Science 1991; 251: 288–292.

48. Yeaman C, Wang D, Paz-Prieto I, Torbet BE, Tenen DG, Friedman AD. CEBPalpha binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment. Blood 2007; 109: 3136–3142.

49. Degrugillier D, Thielgaard-Monch K, Hasemann MS, Anderson K, Damgaard I et al. Loss of CEBPalpha cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocytic lineage. J Exp Med 2005; 202: 85–96.

50. Taaksen E, Bullinger L, Corbacioglu A, Sanders MP, Erpelink C, Wouters BJ et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPalpha mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011; 117: 2469–2475.

51. Holliin IK, van den Heuvel-Eibrink MM, Arensen-Peters ST, Zimmermann M, Peeters JK, Vaal PJ et al. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica 2011; 96: 384–392.

52. Peramangalam PS, Dengler V, Ho PA, Preudhomme C, Meshinchi S et al. CEBPalpha regulated microRNA-34a targets EZF3 during granulopoiesis and is down-regulated in AML with CEBPalpha mutations. Blood 2010; 116: 5638–5649.

53. Nakaz L, Lonard DM, Smith CL, Lev-Lehman E, Tsi S, Tsai MJ et al. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 1999; 19: 1182–1189.

54. Singh SM, Trivedi AK, Behre G. CEBPalpha-Signed mutations reduce granulocytic differentiation in human leukemic K562 cells. Biochem Biophys Res Commun 2003; 309: 692–694.

55. Pal P, Kanaujya JK, Lochab S, Tripathi SB, Bhatt ML, Singh PK et al. 2-D gel electrophoresis-based proteomic analysis reveals that ormeloxifen induces G0-G1 growth arrest and ERK-mediated apoptosis in chronic myeloid leukemia cells K562. Proteomics 2011; 11: 1517–1529.